OC
OCUL
OCULAR THERAPEUTIX, INC
$8.94
+2.76%
$2.0B
No data for this timeframe.
Vol
Market Cap$2.0B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders50 funds
Inst. Value$965.8M
Inst. Activity20 buys / 10 sells
Insider Activity1B / 16S
Insider Net $-$1.7M
SEC Reports7
Press Releases3
Recent Activity
Jun 12, 2026
SEC
Ocular Therapeutix filed an 8-K reporting the formal appointment of Jason Robins as CFO (previously interim) and stockho
8-K — Impact 3/10
Jun 10, 2026
Insider
Williams Leslie J. was granted 14,000 shares
Director
Jun 10, 2026
Insider
Williams Leslie J. was granted 44,000 shares
Director
Jun 10, 2026
Insider
RAINES MERILEE was granted 14,000 shares
Director
Jun 8, 2026
short_volume
Short Volume: OCUL — 55.8% short (0.4M / 0.6M)
Short: 355,337 | Exempt: 71 | TRF Vol: 637,317 | Short Ratio: 55.8% | Off-exchange volume (dark pool
Jun 4, 2026
Press
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple dat
Impact 7/10
May 28, 2026
SEC
Four OCUL insiders, including the Chief Scientific Officer and Chief Development Officer, conducted open-market sales of
CLUSTER — Impact 3/10
May 5, 2026
SEC
Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was belo
PRESS-RELEASE — Impact 6/10
Price Targets
$26.00
+190.8% upside
Strong Buy
Current $8.94
Low $18.00
Median $27.00
High $34.00
11 analysts
$18.00
$34.00
Analyst Ratings
6Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | RBC Capital | REITERATE | Outperform → Outperform |
| May 5, 2026 | Needham | REITERATE | Buy → Buy |
| Apr 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 3, 2026 | Clear Street | MAINTAIN | Buy → Buy |
| Feb 20, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.41 ▼ -21.5% | $-0.42 — $-0.38 | -4% YoY | 5 |
| Next Q | $-0.41 ▼ -15.8% | $-0.45 — $-0.38 | -9% YoY | 5 |
| Current FY | $-1.62 | $-1.70 — $-1.55 | -14% YoY | 4 |
| Next FY | $-1.60 | $-1.75 — $-1.30 | 1% YoY | 4 |
Latest Reports
NEUTRAL
8-K
3/10
Ocular Therapeutix filed an 8-K reporting the formal appointment of Jason Robins as CFO (previously interim) and stockho
Jun 12, 2026
BULLISH
Press
7/10
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple dat
Jun 4, 2026
NEUTRAL
CLUSTER
3/10
Four OCUL insiders, including the Chief Scientific Officer and Chief Development Officer, conducted open-market sales of
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $276.6M | — |
| BlackRock, Inc. | $136.6M | ADD |
| Avoro Capital Advisors LLC | $104.3M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $73.9M | — |
| ALLIANCEBERNSTEIN L.P. | $50.1M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Williams Leslie | A | $0.00 |
| Jun 10, 2026 | Williams Leslie | A | $0.00 |
| Jun 10, 2026 | RAINES MERILEE | A | $0.00 |
| Jun 10, 2026 | RAINES MERILEE | A | $0.00 |
| Jun 10, 2026 | LINDSTROM RICHARD | A | $0.00 |
50 institutional holders with $965.8M total value (112,309,013 shares) as of 2026-Q1. Top holders: FMR, BlackRock,, Avoro. Net buying activity: 20 institutions added/increased vs 10 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 32,653,764 | $276.6M | 28.6% | — |
| 2 | BlackRock, Inc. | 16,132,931 | $136.6M | 14.1% | ADD +47.8% |
| 3 | Avoro Capital Advisors LLC | 12,315,000 | $104.3M | 10.8% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 8,719,039 | $73.9M | 7.6% | — |
| 5 | ALLIANCEBERNSTEIN L.P. | 4,129,687 | $50.1M | 5.2% | NEW |
| 6 | Point72 Asset Management, L.P. | 5,534,985 | $46.9M | 4.9% | DOUBLED +444.6% |
| 7 | STATE STREET CORP | 4,708,419 | $39.9M | 4.1% | — |
| 8 | BALYASNY ASSET MANAGEMENT L.P. | 2,692,622 | $22.8M | 2.4% | DOUBLED +252.6% |
| 9 | TWO SIGMA INVESTMENTS, LP | 1,830,159 | $15.5M | 1.6% | ADD +62.5% |
| 10 | Woodline Partners LP | 1,667,609 | $14.1M | 1.5% | — |
| 11 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,594,666 | $13.5M | 1.4% | — |
| 12 | Invesco Ltd. | 1,536,779 | $13.0M | 1.3% | ADD +71.6% |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,461,177 | $12.4M | 1.3% | ADD +29.9% |
| 14 | MORGAN STANLEY | 1,280,119 | $10.8M | 1.1% | ADD +45.6% |
| 15 | VANGUARD FIDUCIARY TRUST CO | 1,245,024 | $10.5M | 1.1% | — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 1,147,982 | $9.7M | 1.0% | ADD +45.1% |
| 17 | GOLDMAN SACHS GROUP INC | 1,110,366 | $9.4M | 1.0% | — |
| 18 | Artisan Partners Limited Partnership | 902,931 | $7.6M | 0.8% | — |
| 19 | RAYMOND JAMES FINANCIAL INC | 859,485 | $7.3M | 0.8% | — |
| 20 | MARSHALL WACE, LLP | 740,803 | $6.3M | 0.6% | TRIM -46.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | DOUBLED | 1,016,248 | 5,534,985 | +444.6% | $46.9M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 763,559 | 2,692,622 | +252.6% | $22.8M | 2026-Q1 |
| Invesco Ltd. | ADD | 895,687 | 1,536,779 | +71.6% | $13.0M | 2026-Q1 |
| MORGAN STANLEY | ADD | 879,144 | 1,280,119 | +45.6% | $10.8M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 791,200 | 1,147,982 | +45.1% | $9.7M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 1,377,203 | 740,803 | -46.2% | $6.3M | 2026-Q1 |
| Verition Fund Management LLC | DOUBLED | 171,606 | 527,338 | +207.3% | $4.5M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 601,360 | 397,092 | -34.0% | $3.4M | 2026-Q1 |
| Pictet Asset Management Holding SA | DOUBLED | 27,272 | 362,596 | +1229.6% | $2.7M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 169,673 | 258,164 | +52.2% | $2.2M | 2026-Q1 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | ADD | 159,746 | 234,547 | +46.8% | $2.0M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | 92,648 | 227,808 | +145.9% | $1.9M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | DOUBLED | 18,139 | 165,984 | +815.1% | $1.4M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | DOUBLED | 59,300 | 188,368 | +217.7% | $1.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 94,426 | 152,884 | +61.9% | $1.3M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 162,810 | 111,005 | -31.8% | $940.2K | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | NEAR_EXIT | 4,229,202 | 68,500 | -98.4% | $580.5K | 2026-Q1 |
| Assenagon Asset Management S.A. | NEAR_EXIT | 620,814 | 45,600 | -92.7% | $386.2K | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | NEAR_EXIT | 395,591 | 42,533 | -89.2% | $360.3K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 11,210 | 29,270 | +161.1% | $247.9K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 31,941 | 18,173 | -43.1% | $154.3K | 2026-Q1 |
| Allianz Asset Management GmbH | TRIM | 27,300 | 15,200 | -44.3% | $128.7K | 2026-Q1 |
| CWM, LLC | DOUBLED | 929 | 12,377 | +1232.3% | $104.8K | 2026-Q1 |
| Brevan Howard Capital Management LP | NEAR_EXIT | 305,815 | 12,296 | -96.0% | $104.1K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 2,572 | 5,957 | +131.6% | $50.5K | 2026-Q1 |
13 unique insiders with 33 transactions. Net insider value: -$1.7M ($461.4K bought, $2.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Williams Leslie J. | Director | AWARD | 14,000 | — | — |
| Jun 10, 2026 | Williams Leslie J. | Director | AWARD | 44,000 | — | — |
| Jun 10, 2026 | RAINES MERILEE | Director | AWARD | 14,000 | — | — |
| Jun 10, 2026 | RAINES MERILEE | Director | AWARD | 44,000 | — | — |
| Jun 10, 2026 | LINDSTROM RICHARD L MD | Director | AWARD | 44,000 | — | — |
| Jun 10, 2026 | LINDSTROM RICHARD L MD | Director | AWARD | 14,000 | — | — |
| Jun 10, 2026 | Hong Seung Suh | Director | AWARD | 14,000 | — | — |
| Jun 10, 2026 | Graves Adrienne L | Director | AWARD | 14,000 | — | — |
| Jun 10, 2026 | Robins Jason Shand | Chief Financial Officer | AWARD | 15,441 | — | — |
| Jun 10, 2026 | Graves Adrienne L | Director | AWARD | 44,000 | — | — |
| Jun 10, 2026 | Hong Seung Suh | Director | AWARD | 44,000 | — | — |
| Jun 10, 2026 | Robins Jason Shand | Chief Financial Officer | AWARD | 14,024 | — | — |
| Jun 10, 2026 | Warden Charles M | Director | AWARD | 14,000 | — | — |
| Jun 10, 2026 | Warden Charles M | Director | AWARD | 44,000 | — | — |
| Jun 3, 2026 | Waheed Nadia | Chief Medical Officer | SELL | 14,828 | $8.27 | $122.6K |
| May 28, 2026 | Dugel Pravin | See Remarks | GIFT | 394,696 | — | — |
| May 26, 2026 | Kaiser Peter | Chief Development Officer | SELL | 2,967 | $8.20 | $24.3K |
| May 26, 2026 | Nayak Sanjay | Chief Strategy Officer | SELL | 1,858 | $8.20 | $15.2K |
| May 26, 2026 | Heier Jeffrey S. | Chief Scientific Officer | SELL | 3,018 | $8.20 | $24.7K |
| May 26, 2026 | Dugel Pravin | See Remarks | SELL | 21,156 | $8.20 | $173.5K |
| Apr 9, 2026 | Dugel Pravin | See Remarks | GIFT | 394,696 | — | — |
| Feb 23, 2026 | Dugel Pravin | See Remarks | SELL | 20,056 | $8.28 | $166.1K |
| Feb 23, 2026 | Kaiser Peter | Chief Development Officer | SELL | 2,810 | $8.28 | $23.3K |
| Feb 23, 2026 | Heier Jeffrey S. | Chief Scientific Officer | SELL | 3,057 | $8.28 | $25.3K |
| Feb 23, 2026 | Nayak Sanjay | Chief Strategy Officer | SELL | 1,759 | $8.28 | $14.6K |
| Feb 20, 2026 | Waheed Nadia | Chief Medical Officer | SELL | 3,510 | $7.74 | $27.2K |
| Feb 20, 2026 | LINDSTROM RICHARD L MD | Director | BUY | 60,229 | $7.66 | $461.4K |
| Feb 12, 2026 | Dugel Pravin | See Remarks | SELL | 124,882 | $9.04 | $1.1M |
| Feb 12, 2026 | Notman Donald | Chief Operating Officer | SELL | 11,446 | $9.04 | $103.5K |
| Feb 12, 2026 | Nayak Sanjay | Chief Strategy Officer | SELL | 10,348 | $9.04 | $93.5K |
| Feb 12, 2026 | Waheed Nadia | Chief Medical Officer | SELL | 7,863 | $9.04 | $71.1K |
| Feb 4, 2026 | Notman Donald | Chief Operating Officer | SELL | 6,035 | $8.54 | $51.5K |
| Feb 2, 2026 | Notman Donald | Chief Operating Officer | SELL | 5,455 | $9.14 | $49.9K |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 3 mixed, 4 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
3/10
Ocular Therapeutix filed an 8-K reporting the formal appointment of Jason Robins as CFO (previously
Jun 12, 2026
NEUTRAL
CLUSTER
3/10
Four OCUL insiders, including the Chief Scientific Officer and Chief Development Officer, conducted
May 28, 2026
MIXED
PRESS-RELEASE
6/10
Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenu
May 5, 2026
NEUTRAL
8-K
5/10
Ocular Therapeutix reported Q1 2026 net revenue of $10.8M (up 0.8% YoY), essentially flat, and a net
May 5, 2026
NEUTRAL
DEFA14A
3/10
Ocular Therapeutix filed a DEFA14A (definitive additional proxy soliciting materials) providing noti
Apr 30, 2026
MIXED
CLUSTER
5/10
A cluster of insider transactions at Ocular Therapeutix (OCUL) shows mixed activity: one significant
Feb 26, 2026
MIXED
CLUSTER
6/10
A cluster of insider transactions at Ocular Therapeutix (OCUL) over the past week shows mixed activi
Feb 26, 2026
BULLISH
7/10
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will
Jun 4, 2026
BULLISH
8/10
Ocular Therapeutix presented additional Week 52 post-hoc data from its SOL-1 Phase 3 trial for AXPAX
Apr 13, 2026
NEUTRAL
3/10
Ocular Therapeutix announced upcoming presentations of Phase 3 data for its investigational therapy
Apr 1, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 18 analysts: 6 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$26.00 mean target
+190.8% upside
Strong Buy (1.36)
$18.00 Low
$34.00 High
| Metric | Value |
|---|---|
| Current Price | $8.94 |
| Target Low | $18.00 |
| Target Mean | $26.00 |
| Target Median | $27.00 |
| Target High | $34.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.36) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.41 | $-0.42 | $-0.38 | -4.3% | -21.5% | 0↑ 1↓ | $0.0B | -1.9% | 5 |
| Next Q 2026-09-30 |
$-0.41 | $-0.45 | $-0.38 | -8.9% | -15.8% | 0↑ 1↓ | $0.0B | -3.6% | 5 |
| Current FY 2026-12-31 |
$-1.62 | $-1.70 | $-1.55 | -14.0% | +0.0% | 0↑ 1↓ | $0.1B | -0.1% | 4 |
| Next FY 2027-12-31 |
$-1.60 | $-1.75 | $-1.30 | 1.4% | +0.0% | 0↑ 2↓ | $0.1B | 123.8% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.410 | |
| 7d ago | $-0.338 | -0.072 |
| 30d ago | $-0.338 | -0.072 |
| 60d ago | $-0.338 | -0.072 |
| 90d ago | $-0.380 | -0.030 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| May 5, 2026 | Needham | REITERATE | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 3, 2026 | Clear Street | MAINTAIN | Buy | Buy |
| Feb 20, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
short_volume
Short Volume: OCUL — 55.8% short (0.4M / 0.6M)
Short: 355,337 | Exempt: 71 | TRF Vol: 637,317 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
other
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceut
Jun 4, 2026
fda
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
<p>BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company comm
Jun 1, 2026
short_volume
Short Volume: OCUL — 61.8% short (0.5M / 0.9M)
Short: 540,515 | Exempt: 0 | TRF Vol: 873,993 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
other
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated b
May 15, 2026
short_volume
Short Volume: OCUL — 57.0% short (0.5M / 0.9M)
Short: 537,718 | Exempt: 672 | TRF Vol: 943,231 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 8, 2026
activist
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated b
May 5, 2026
earnings
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
<p align="center"><em>Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R</
May 5, 2026
earnings_calendar
OCUL Q1 2026 Earnings After Market Close — 2026-05-05
May 4, 2026
earnings_calendar
OCUL Q1 2026 Earnings After Market Close — 2026-05-04
May 1, 2026
short_volume
Short Volume: OCUL — 58.7% short (0.6M / 1.0M)
Short: 559,182 | Exempt: 500 | TRF Vol: 952,906 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: OCUL — 64.6% short (0.6M / 0.9M)
Short: 581,457 | Exempt: 1,066 | TRF Vol: 900,672 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
other
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
Ocular’s Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 <pre>Ocular’
Apr 14, 2026
other
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>BEDFORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceu
Apr 13, 2026
fda
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
<p align="center"><em>New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control<